Navigation Links
Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
Date:3/7/2011

their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

As we expanded our number of Tumorgraft models, we began to offer leading pharmaceutical and biotechnology companies the benefits of our Tumorgraft Technology Platform for their pharmaceutical development programs.  We provide Translational Oncology Solutions, or TOS, (previously referred to as Preclinical eValuation services) that we believe are predictive of clinical outcomes and that might provide for a faster and less expensive path to drug approval.  These services utilize Tumorgrafts to evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents.  TOS also includes biomarker discovery and the identification of novel drug combinations.  We began deriving revenues from our TOS services in fiscal 2009 and completed our first full year of business in fiscal 2010.

Full details of the Company's financial results will be available in the Company's Form 10-Q at www.championsbiotechnology.com.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors.  Although the Co
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Additions to its Management Team
2. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
3. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
4. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
7. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
8. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
11. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Mich. , June 1, 2015  Neogen Corporation (NASDAQ: ... assets of Sterling Test House, a leading commercial food testing ... that the acquired laboratory will serve as a base for ... Sterling Test House was incorporated ... all of the food safety and water quality testing for ...
(Date:6/1/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") ... at the ERA-EDTA Congress in London, England ... a First-in-Class Epigenetic BET-Inhibitor, on Key Renal Parameters in ... Disease (CKD); a Post-hoc Analysis of Patients from the ... Dr. Kam Kalantar-Zadeh , Professor and Chief, Division ...
(Date:6/1/2015)... 1, 2015  Berg, a biopharmaceutical company committed to ... clinical research from its trials using its cancer drug ... data on triple negative breast cancer, at the 51 ... Clinical Oncology (ASCO), May 29 – June 2 in ... 31510 is one of the first cancer drugs guided ...
(Date:6/1/2015)... , June 1, 2015 ... that it will be participating in the Jefferies 2015 ... on Tuesday, June 2, 2015. Jeff ... question and answer session at 10:00 a.m. ET (3:00 ... be available on the Presentations and Webcasts section of ...
Breaking Biology Technology:Neogen acquires India food safety company 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 2Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 3Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA) 4Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3
... year,s first , quarter , - Total revenue of ... million , - Earnings per share of $0.29, an increase of ... - New products launched containing life,sDHA(TM) in a variety of , ... demonstrate the strong , leverage in our businessCOLUMBIA, Md., ...
... MOUNTAIN VIEW, Calif., March 4 The Healthcare ... pleased to announce its 2009 Quarterly Analyst Briefing ... be held on Thursday, March 5, 2009 at ... industry has witnessed healthy growth and is experiencing ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... fourth quarter of 2008 was $334,041 compared to $174,071 for ... from the sale of PCT products and services was $233,256 ... $118,703 for the same period in 2007, a 97% increase. ...
Cached Biology Technology:Martek Announces First Quarter 2009 Financial Results 2Martek Announces First Quarter 2009 Financial Results 3Martek Announces First Quarter 2009 Financial Results 4Martek Announces First Quarter 2009 Financial Results 5Martek Announces First Quarter 2009 Financial Results 6Martek Announces First Quarter 2009 Financial Results 7Martek Announces First Quarter 2009 Financial Results 8Martek Announces First Quarter 2009 Financial Results 9Martek Announces First Quarter 2009 Financial Results 10Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 3Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 4Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 5Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 6Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 7Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 8
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Feb. 1, 2008) This months issue of ... methods to understand developmental processes in plants and flies. ... on the Web site for Cold Spring Harbor Protocols ... use of RNAi to investigate gene function in fruit flies. ...
... the role of a gene important to the embryonic ... coordination of differentiation of immature neural cells with the ... now, the mechanisms regulating these distinct cellular activities have ... published in the Feb. 15 issue of Development. ...
... Scientists at the University of Alabama at Birmingham ... uncover new details about the infectious potency of poxviruses, ... infections can subvert the bodys immune system. Having ... the discovery of new drugs to combat inflammation and ...
Cached Biology News:RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols 2Trainor Lab characterizes gene essential for prenatal development of nervous system 2Poxvirus potency uncovered in new atomic map 2
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: